CompletedPhase 2NCT00098683
Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes
Studying Myelodysplastic neoplasm with low blasts
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Prasad Mathew, MDUniversity of New Mexico Cancer Center
- Intervention
- amifostine trihydrate(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 1-21 years · All sexes
- Timeline
- 2005 – 2009
Study locations (30)
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Jonathan Jaques Children's Cancer Center at Miller Children's Hospital, Long Beach, California, United States
- Children's Hospital Central California, Madera, California, United States
- Kaiser Permanente Medical Center - Oakland, Sacramento, California, United States
- Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, Connecticut, United States
- Lee Cancer Care of Lee Memorial Health System, Fort Myers, Florida, United States
- University of Florida Shands Cancer Center, Gainesville, Florida, United States
- Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
- Miami Children's Hospital, Miami, Florida, United States
- Sacred Heart Cancer Center at Sacred Heart Hospital, Pensacola, Florida, United States
- All Children's Hospital, St. Petersburg, Florida, United States
- St. Joseph's Cancer Institute at St. Joseph's Hospital, Tampa, Florida, United States
- Kaplan Cancer Center at St. Mary's Medical Center, West Palm Beach, Florida, United States
- Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00098683 on ClinicalTrials.govOther trials for Myelodysplastic neoplasm with low blasts
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07328191Quality of Life-Guided Transfusion in Refractory MDS or AMLCentre Hospitalier Universitaire de Nice
- RECRUITINGPHASE2NCT06918834Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome PatientsInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT07019155Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition VariantsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNCT06144515Collection of Samples of Bone Marrow Aspiration From Patients With Myelodysplastic SyndromeMinovia Therapeutics Ltd.
- RECRUITINGPHASE2NCT05924100Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TDAssociazione Qol-one
- RECRUITINGPHASE1NCT05473910A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem TransplantationTScan Therapeutics, Inc.
- RECRUITINGNCT02269592Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeDana-Farber Cancer Institute
See all trials for Myelodysplastic neoplasm with low blasts →